Telo Genomics (TELO.V) was granted three of its pending patent applications today, according to a press release.

The company already has patents pertaining to hematological cancers in the United States and Alzheimer’s disease in the United States and Canada. Their United States patent application on liquid biopsy is still pending.

“The issuance of three additional final patents further augments Telo’s already-strong IP portfolio. Blood cancers and liquid biopsy are at the core of the company’s commercialization program. The issuance of these patents assures the long-term protection of the TeloView platform as a prognostic/diagnostic tool for these diseases,” said Sabine Mai, Telo director and chair of the clinical and scientific advisory board.

Specifically, these patents include:

  • Diagnostic methods for hematological disorders (hematological cancers) (Canada);
  • Methods for characterizing and isolating circulating tumour cell subpopulations (liquid biopsy) (Canada);
  • Methods of diagnosing Alzheimer’s disease (Europe).

The company has acquired intellectual property protection in jurisdictions around the world and owns a portfolio of patents and pending patent applications in the United States, Canada and the European Union. The IP covers their core technology and its applications. TeloView is trademarked in the United States, Canada, Europe and Israel, in addition to the company’s existing and pending intellectual property.

In other news, the company reports that Leede Jones Gable and Mackie Research Corp. have exercised 5,026,800 of clients’ and brokers’ warrants for $944,180 and neither Leede nor Mackie will be soliciting further warrant exercises.

—Joseph Morton

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Health Science
American patents
Canadian patents
European patents
intellectual property
Telo Genomics
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x